1. Home
  2. HG vs ABCL Comparison

HG vs ABCL Comparison

Compare HG & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

N/A

Current Price

$38.32

Market Cap

3.8B

Sector

N/A

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$9.73

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HG
ABCL
Founded
2013
2012
Country
Bermuda
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
HG
ABCL
Price
$38.32
$9.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
14
Target Price
★ $39.86
$18.69
AVG Volume (30 Days)
404.0K
★ 2.8M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 5.29%
N/A
EPS Growth
★ 51.23
10.91
EPS
★ 3.54
N/A
Revenue
★ $2,905,524,000.00
$75,128,000.00
Revenue This Year
$0.13
N/A
Revenue Next Year
$2.38
$13.74
P/E Ratio
$10.67
★ N/A
Revenue Growth
24.70
★ 160.56
52 Week Low
$25.53
$2.75
52 Week High
$39.50
$14.98

Technical Indicators

Market Signals
Indicator
HG
ABCL
Relative Strength Index (RSI) 61.13 33.61
Support Level $33.53 $3.45
Resistance Level N/A $12.91
Average True Range (ATR) 0.99 0.84
MACD 0.01 -0.22
Stochastic Oscillator 71.43 1.84

Price Performance

Historical Comparison
HG
ABCL

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: